Drug extrapyramidal side-effects or not: is there a dextromethorphan phenotype difference?

Area of Science:

• Pharmacogenetics
• Neuropharmacology

Background:

• Cytochrome P450 2D6 (CYP2D6) metabolizes numerous psychotropic medications.
• Polymorphisms in CYP2D6 are linked to altered drug metabolism and potential adverse effects.
• Extrapyramidal side-effects (EPS) are common adverse reactions to antipsychotic and antidepressant drugs.

Purpose of the Study:

• To investigate the association between CYP2D6 metabolizer phenotype and the occurrence of EPS in psychiatric patients.
• To determine if CYP2D6 poor metabolizer status is a risk factor for developing EPS.

Main Methods:

• Compared CYP2D6 metabolizer phenotype using a dextromethorphan test in two groups of adult psychiatric patients.
• Group 1: 31 patients with drug-induced EPS. Group 2: 31 matched patients without EPS.
• Defined poor metabolizers by a dextromethorphan metabolic ratio > 0.3.

Main Results:

• 13 out of 31 patients (41.9%) in Group 1 were identified as poor CYP2D6 metabolizers.
• Only 2 out of 31 patients (6.4%) in Group 2 were poor CYP2D6 metabolizers.
• A significantly higher prevalence of poor metabolizers was observed in patients experiencing EPS.

Conclusions:

• CYP2D6 poor metabolizer status may be a risk factor for developing drug-induced extrapyramidal side-effects.
• In patients with likely saturated CYP2D6 activity, the risk of EPS might be elevated.
• Consideration of psychotropic drugs with lower EPS risk is recommended for patients with impaired CYP2D6 metabolism.